Carter+Co is proud to recognize longtime client Sidewinder Therapeutics following the company’s announcement of a $137 million Series B financing. This significant milestone marks another exciting step forward for a company that is doing meaningful work in the fight against cancer. Sidewinder Therapeutics is a San Diego-based biopharmaceutical company developing next-generation bispecific antibody-drug conjugates designed to improve precision and effectiveness in cancer treatment. The company’s technology is focused on targeting tumor-specific receptor co-complexes in order to enhance drug delivery to cancer cells while helping avoid healthy tissue. Sidewinder has stated that the new financing will help advance its programs toward clinical development, including its lead program, which is expected to enter the clinic in 2027. We have had the pleasure of working with Sidewinder for years, and it has been exciting to watch the company continue to build momentum. Long-term client relationships are a core part of what we value at Carter+Co, and it is always rewarding to see our clients achieve major milestones as they grow and scale. We congratulate the Sidewinder team on this outstanding achievement and look forward to their continued success in the years ahead.